Registry of Asthma Patients Initiating

Brief description of study

Participant in this observational research study sponsored by Regeneron Pharmaceuticals, Inc., are being asked to participate because they are receiving treatment with dupilumab, since you are currently being treated for asthma by a study participating physician. The study is being done to characterize and collect long term data on patients 12 years and older with moderate to severe asthma, who receive treatment with dupilumab (also known as DUPIXENT®). DUPIXENT is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe asthma, as well as for atopic dermatitis and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP, long-term blocked up or runny nose (chronic rhinosinusitis) with abnormal growths in the nose (nasal polyps)).

Clinical Study Identifier: s20-01492
Principal Investigator: Erin Michelle Banta.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.